MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: medicinova.com
SC 13D/A - MEDICINOVA INC (0001226616) (Subject)
10-Q - MEDICINOVA INC (0001226616) (Filer)
8-K - MEDICINOVA INC (0001226616) (Filer)
10-Q - MEDICINOVA INC (0001226616) (Filer)
ARS - MEDICINOVA INC (0001226616) (Filer)
DEFA14A - MEDICINOVA INC (0001226616) (Filer)
DEF 14A - MEDICINOVA INC (0001226616) (Filer)
8-K - MEDICINOVA INC (0001226616) (Filer)
10-K - MEDICINOVA INC (0001226616) (Filer)
S-8 POS - MEDICINOVA INC (0001226616) (Filer)
S-8 POS - MEDICINOVA INC (0001226616) (Filer)
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL,
LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract was accepted for presentation regarding a clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS Phase 2b/ 3 study at the 2024 Annual NEALS Meeting to be held October 21-24, 2024 (a hybrid meeting in Clearwater, Florida and Online). The presentation will be in poster format and be presented by lead Principal Investigator of the clinical trial, Björn Oskarsson, MD, FAAN, Associate Professor of Neurology at Ja
LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tigh
Company to rededicate efforts toward updating stakeholders oncorporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) and focused on development of novel treatments for neurodegenerative diseases, malignant brain cancers, and metabolic diseases, announces that its Chief Business Officer, David H. Crean, Ph.D., will assume management of the Company's investor engagement, corporate communications, and public relations activities. Dr. Crean will now lead the charge to expand and enh
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis in various cancers including pancreatic cancer, lung cancer, breast cancer, colorectal cancer, melanoma, and ovarian cancer. Once issued, this patent is expected to expire no earlier than July 2042. The allowed claims cover the use of MN-166 (ibudilast) in combination with one
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Gilbert Youssef, M.D. at Harvard Medical School, Attending Physician, Center for Neuro-Oncology at Dana-Farber Cancer Institute and Brigham and Women's Hospital, presented new data and results of a Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma (GBM) at the American Society of Clinical Oncology (ASCO) Annual meeting 2024 held May 31- June 4th in Chicago, IL. The highlights of presentation entitled "Phase 1b/
LA JOLLA, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova conducted two poster presentations at the 92nd European Atherosclerosis Society (EAS) 2024 Congress held online May 26-29, 2024. MediciNova's Chief Medical Officer, Kazuko Matsuda, MD PhD MPH presented an update on the Company's "STUDY PROTOCOL TO EVALUATE MN-001'S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) (Abstract # 810) ", which included Clinical background, Study objectives,
LA JOLLA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the prevention of metastasis of eye cancer. Once issued, this patent is expected to expire no earlier than July 2042. The allowed claims cover the use of MN-166 (ibudilast) for preventing, ameliorating, or minimizing metastasis of eye cancer. The allowed claims specifically cover the use of MN-166 (ibudilas
LA JOLLA, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome (ARDS). Once issued, this patent is expected to expire no earlier than January 2042. The allowed claims cover the use of MN-166 (ibudilast) for treating chlorine-induced ARDS. The allowed claims cover the use of MN-166 (ibudilast) as a
LA JOLLA, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an issue notification from the U.S. Patent and Trademark Office for a new patent which covers extended-release oral formulations of MN-166 (ibudilast). This new patent is expected to expire no earlier than September 2040. The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibudilast). Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "We a
Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00
Maxim Group initiated coverage of MediciNova with a rating of Buy and set a new price target of $15.00
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
3 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
4 - MEDICINOVA INC (0001226616) (Issuer)
The highlights of presentation are as follows: The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment. The combination of Temozolomide (TMZ) and MN-166 was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse events were Lymphopenia, Leukopenia, Thrombocytopenia and Neutropenia. Preclinical data has shown improved survival with the combination of Ibudilast and PD-1 or PD-L1 antibody therapy compared to treatment with ibudilast alone or PD-1/PD-L1 antibody alone, suggesting a potential promising therapeutic benefit of this combinati
Gainers Longeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. Etao International Co (NASDAQ:ETAO) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. 180 Life Sciences (NASDAQ:ATNF) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. Inovio Pharmaceuticals (NASDAQ:INO) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. Gossamer Bio
Abstract Number: 2106 Title: Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM) Session Title: Rapid Oral Abstract – Central Nervous System Tumors Session Date: June 2, 2024 Session Time: 11:30 AM – 1:00 PM
Gainers Lixte Biotechnology (NASDAQ:LIXT) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. Nutriband (NASDAQ:NTRB) shares rose 24.34% to $3.78. The company's market cap stands at $31.9 million. NovoCure (NASDAQ:NVCR) stock rose 17.9% to $15.41. The company's market cap stands at $1.6 billion. Strata Skin Sciences (NASDAQ:SSKN) shares increased by 14.93% to $0.53. The market value of their outstanding shares is at $18.5 million. As per the news, the Q4 earnings report came out today. Nuvation Bio (NYSE:NUVB) shares moved upwards by 11.11% to $3.2. The market value of their outstanding shares is
Shares of MariaDB plc (NYSE:MRDB) rose sharply in today’s pre-market trading after Progress Software (NASDAQ:PRGS) announced that it is possibly considering an offer for the company. MariaDB shares jumped 100.4% to $0.4530 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Destiny Tech100 Inc (NASDAQ:DXYZ) rose 52.9% to $13.76 in pre-market trading after gaining 9% on Tuesday. PaySign, Inc. (NASDAQ:PAYS) gained 25.2% to $4.23 in pre-market trading after the company announced better-than-expected fourth-quarter results. Hitek Global Inc. (NASDAQ:HKIT) gained 19.1% to $1.69 in pre-market trading. The ONE Group Hospitality, Inc. (NASDAQ:STKS) shar
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled "STUDY PROTOCOL TO EVALUATE MN-001'S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)" and "MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX" have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.